Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | FABP2 | P12104 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8754966 | 1.00 | APP (0.58) | APPAKR1C3AKR1C2CNR1CNR2 | |
| SCHEMBL7327823 | 0.87 | AKR1C3 (0.50) | APPAKR1C3AKR1C2CYP2C9CYP3A4 | |
| SCHEMBL7326882 | 0.86 | AKR1C3 (0.49) | APPAKR1C3AKR1C2CYP2C9CYP3A4 | |
| SCHEMBL8755138 | 0.85 | APP (0.78) | APPAKR1C3AKR1C2CYP2C9CYP3A4 | |
| SCHEMBL3938352 | 0.85 | APP (0.78) | APPAKR1C3AKR1C2CYP2C9CYP3A4 | |
| SCHEMBL8811656 | 0.83 | AKR1C3 (0.46) | APPAKR1C3AKR1C2CYP2C9CYP3A4 | |
| SCHEMBL4211223 | 0.82 | RORC (0.46) | APPAKR1C3AKR1C2CYP2C9PTGS1 | |
| SCHEMBL7472692 | 0.80 | CNR1 (0.51) | APPAKR1C3AKR1C2CNR1CNR2 | |
| SCHEMBL6333306 | 0.79 | AKR1C3 (0.48) | APPAKR1C3AKR1C2CNR1CNR2 | |
| SCHEMBL10704177 | 0.79 | APP (0.60) | APPAKR1C3AKR1C2CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150183737-A1 | COMPOSITIONS AND METHODS FOR SUBSTRATE-SELECTIVE INHIBITION OF ENDOCANNABINOID OXYGENATION | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-07-02 | — | — | US | disclosed |
| WO-2014138343-A1 | ANTIBIOTIC CONJUGATES WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS | ALLERGAN, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-8778298-B2 | Isotope labeled 2-arylpropionic acid compounds and process for production of same, and molecular probe for positron emission tomography and method for imaging of cyclooxygenase and the like using same | RIKEN (JP) | 2014-07-15 | — | — | US | disclosed |
| WO-2014015341-A2 | COMPOSITIONS AND METHODS FOR SUBSTRATE-SELECTIVE INHIBITION OF ENDOCANNABINOID OXYGENATION | VANDERBILT UNIVERSITY (US) | 2014-01-23 | — | — | WO | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| EP-0979226-B1 | ISOXAZOLE DERIVATIVES | SUMITOMO PHARMA (JP) | 2005-11-09 | — | — | EP | disclosed |
| WO-2005092062-A2 | COMPOUNDS FOR NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2005-10-06 | — | — | WO | disclosed |
| US-6100260-A | ((3-(1-(2-FLUORO-BIPHENYL-4-YL)-ETHYL)-ISOXAZOL-5-YLIMINO) -MORPHOLIN-4-YL-M ETHYL)-AMINE, FOR EXAMPLE; ADMINISTERING TO TREAT AUTOIMMUNE DISEASES AND INFLAMMATION | SUMITOMO PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183737-A1 | COMPOSITIONS AND METHODS FOR SUBSTRATE-SELECTIVE INHIBITION OF ENDOCANNABINOID OXYGENATION | CNR2, FAAH2, FAAH | APP 2009/4885AKR1C3 729/4885AKR1C2 821/4885 |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | APP 1/4885AKR1C3 570/4885AKR1C2 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.